Additional file 1 of Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions

Abstract

Additional file 1: Table S1. Injected volumes (ml) per animal and per formulation. Table S2. Median weight (Q1, Q3) in kg for each experimental cattle group at each weighing date. Table S3. Additional mean (SD) pharmacokinetic parameters of ivermectin in cattle plasma. Table S4. Ivermectin extraction results in each depot collected at study end. Table S5. Copolymers extraction results in each depot collected at study end. Table S6. Number of mosquitoes homozygous or heterozygous for the mutated KDR-W allele. Table S7. Number of KIS (A) and VK5 (B) blood-fed mosquitoes followed for their survival throughout the experiment. Table S8. Hazard ratios (HRs), z-values and associated p-values derived from the Cox proportional hazards models for KIS and VK5 mosquitoes. Tables S9–S12. Comparison of the lethal concentrations of formulations. Table S13. Lethal concentration (LC50) for KIS and VK5 mosquitoes over 4-day follow-up period (4-day LC50)